The 2-3 year trial length of BETonMACE is still on the short end of most cardiovascular outcomes trials that last 4-5 years. Plus, BETonMACE serves as a long-term safety trial since with each passing day we're into unchartered territory of duration of RVX-208 treatment. Phase 2's stopped at 6 months. Prematurely ending BETonMACE may invite criticism for the points above. BETonMACE was designed/powered to detect a 30% relative risk reduction in 3-point MACE. But your ethical point is well taken. Perhaps if the 3-point MACE RRR far exceeds 30%, then the data safety monitoring board may recommend an early halt. I would be surprised though. This is a first in class drug (bromodomain-2 selective BET inhibitor). In order for the EMA and hopefully FDA to approve RVX-208/apabetalone, BETonMACE should be completed as planned in my opinion. Also, keep in mind that there will be a study sample size analysis done at around 175 MACE events that may result in the trial changing from 2400 to 3600 patients. Hopefully, we'll hear some updates on this when Michael Sweeney speaks at the October 13th Research and Development Update.